We did not observe an increased risk of prostate cancer with higher serum IGF-2 in the PCPT when analyzed previously, in either finasteride or placebo treatment arms, although men in the highest quartile of serum IGFBP-2 had increased risk of total and low-grade prostate cancers [23]. This evidence concerns the gene IGFBP2 and Familial prostate cancer.